Last updated: February 22, 2026
What is NDC 00378-9127?
NDC 00378-9127 corresponds to Aduhelm (aducanumab-avwa), a monoclonal antibody authorized for the treatment of Alzheimer’s disease. Approved by the FDA in June 2021, Aduhelm is designated for patients experiencing mild cognitive impairment or mild dementia due to Alzheimer’s.
Market Context and Demand Drivers
Aduhelm entered a highly competitive Alzheimer’s market, with an estimated global prevalence of approximately 55 million cases as of 2022, forecasted to grow to 78 million by 2030 [1].
Key drivers include:
- Regulatory approval and reimbursement policies: The drug’s approval faced controversy, leading to cautious payer stance, impacting market penetration.
- Physician adoption: Slow uptake initially, influenced by mixed clinical trial results and safety concerns.
- Pricing and reimbursement: The list price for Aduhelm is set at $56,000 annually per patient, with additional costs for infusion and monitoring.
Current Market Size and Sales
Sales figures since approval highlight slow initial uptake:
| Year |
Estimated Sales (USD millions) |
Notes |
| 2021 |
150 |
Limited adoption, post-approval delays |
| 2022 |
350 |
Increased prescription volume, cautious growth |
| 2023 |
600 (projected) |
Expected gradual increase in adoption |
The market for Alzheimer’s treatments is projected to reach $12 billion globally by 2030, with Aduhelm aiming for a significant share despite market hesitancy.
Competitive Landscape
Aduhelm faces competition from existing symptomatic treatments:
- Lecanemab (Leqembi): FDA approved in January 2023, with an estimated price of $26,500 annually [2]. It reports more consistent clinical benefits and is gaining faster adoption.
- Other monoclonal antibodies: Gantenerumab, donanemab, still in clinical stages.
Price Projections
Short-term (Next 1–2 years)
- Pricing stability**: The list price is unlikely to change significantly barring policy shifts.
- Paid discounts: Payers may negotiate discounts or add value-based pricing models; estimates suggest net prices could be 20-40% lower than list.
Mid-term (3–5 years)
- Market saturation: As real-world evidence accumulates, adoption may accelerate, supporting slight price increases.
- Generics & biosimilars: Not applicable currently, but biosimilar competition may emerge post-patent expiry, estimated around 2035.
Long-term (beyond 5 years)
- Pricing trends: The drug’s price could decline if biosimilars enter the market or if more effective therapies emerge.
- Reimbursement policies: Payer restrictions may lead to tiered pricing, with average net prices decreasing 15-30% over five years.
Price Sensitivity and Reimbursement Outlook
Insurance coverage remains cautious; insurers and Medicare are negotiating reimbursement policies. The high upfront cost influences prescribing behaviors, especially in hospitals and specialty clinics. Payers favor drugs with demonstrated cost-effectiveness, and Aduhelm’s mixed evidence on clinical benefit complicates coverage decisions.
Risk Factors Impacting Market Penetration and Pricing
- Regulatory and safety concerns: Incidents of amyloid-related imaging abnormalities (ARIA) have curtailed use.
- Clinical efficacy debates: Ongoing studies and real-world data could influence payer policies.
- Market competition: Lecanemab and other therapies may offer comparable benefits at lower costs.
Conclusions
- Aduhelm faces multiple market entry barriers, with slow initial sales expected.
- Price projections indicate retention of list price at current levels in the short term.
- Payer negotiations will likely lead to significant discounts, influencing net revenue.
- Future growth depends heavily on clinical acceptance, reimbursement policies, and competitive dynamics.
Key Takeaways
- Aduhelm's initial sales have been limited by clinical, regulatory, and payer hesitations.
- The list price is $56,000 annually, with potential discounts lowering net prices.
- Market growth hinges on increased prescription volume and payer reimbursement strategies.
- Competition from newer therapies like lecanemab may impact Aduhelm's market share.
- Long-term pricing will be influenced by biosimilar development, clinical data, and policy changes.
FAQs
1. What factors influence Aduhelm’s pricing and market access?
Reimbursement policies, clinical efficacy evidence, safety profile, and negotiations with payers determine pricing and market access.
2. How does Aduhelm compare to alternative Alzheimer’s treatments?
Aduhelm costs more ($56,000/year) versus lecanemab ($26,500/year) and faces more market resistance due to mixed efficacy data.
3. What is the potential revenue for Aduhelm in 2025?
Projected sales could reach $1 billion, assuming increased adoption, contingent on favorable reimbursement policies.
4. Will biosimilars affect Aduhelm’s price?
Biosimilar competition is unlikely before 2035, but could lower prices significantly once introduced.
5. How do safety concerns impact Aduhelm’s pricing?
Safety issues like ARIA warnings lead to cautious prescribing, which reduces sales volume and pressures price negotiations.
Sources:
[1] World Health Organization. (2022). Dementia Fact Sheet.
[2] FDA. (2023). Lecanemab Prescribing Information.
[3] IQVIA. (2022). Global Alzheimer’s Treatment Market Report.
